Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

132.52 -0.11 (-0.08%)
Streaming Delayed Price Updated: 12:03 PM EDT, Aug 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,594,578
Open 132.05
Bid (Size) 132.50 (2)
Ask (Size) 132.54 (2)
Prev. Close 132.63
Today's Range 131.81 - 134.34
52wk Range 78.19 - 148.15
Shares Outstanding N/A
Dividend Yield 1.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth. 
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term. 
Via The Motley Fool

Performance

YTD
+29.78%
+29.78%
1 Month
-8.87%
-8.87%
3 Month
+2.56%
+2.56%
6 Month
+15.50%
+15.50%
1 Year
+63.88%
+63.88%

More News

Read More
The Top 7 Stocks to Buy Now: Summer 2024
Via InvestorPlace
Smart Money Is Betting Big In NVO Options
Via Benzinga
FDA Warns Of Overdose Risks With Compounded Wegovy, Ozempic Injections
Via Benzinga
Exposures Product Safety
Novo Nordisk Unusual Options Activity For July 26
Via Benzinga
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Via Benzinga
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
Via Benzinga
NYSE:NVO stands out as a growth opportunity that won't break the bank.
Via Chartmill
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
Via The Motley Fool
3 Overlooked Stocks Poised for a Breakout Very Soon
Via InvestorPlace
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Via The Motley Fool
This Could Send Ozempic's Sales Potential to a Whole Other Level
Via The Motley Fool
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
Via The Motley Fool
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Via Investor's Business Daily
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Via The Motley Fool
Novo Nordisk Shares Decline Amid Competitive Pressure
Via Benzinga
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Via Investor's Business Daily
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Via InvestorPlace
Beware, Wegovy -- Pfizer Is Working on a Competitor
Via The Motley Fool
3 Fabulous Growth Stocks to Buy and Hold Forever
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.